サンプルお申込み

お問い合わせ

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書はパーソナル化されたがん治療薬市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートはパーソナル化されたがん治療薬の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界のパーソナル化されたがん治療薬市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートはパーソナル化されたがん治療薬のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別にパーソナル化されたがん治療薬市場を分類しています。本研究に含まれる主な企業は：Bayer、GlaxoSmithKline、Novartis、Sanofi、Pfizer、Amgen、Merck、Bristol-Myers Squibb、Celgene Corporation、Ariad Pharmaceuticals、Eli Lilly、Hoffmann-La Roche、Boehringer Ingelheim、Johnson and Johnson、Teva Pharmaceuticals

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Immunotherapy
    Targeted Therapy
    Chemotherapy
    Hormone Therapy
    Others

用途別の市場セグメント：
    Breast Cancer
    Blood Cancer
    Gastrointestinal Cancer
    Prostate Cancer
    Skin Cancer
    Lung Cancer
    Others

本レポートの詳細内容
世界のパーソナル化されたがん治療薬市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、パーソナル化されたがん治療薬タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業のパーソナル化されたがん治療薬収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のパーソナル化されたがん治療薬市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、パーソナル化されたがん治療薬市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

パーソナル化されたがん治療薬のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：パーソナル化されたがん治療薬のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：パーソナル化されたがん治療薬の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章パーソナル化されたがん治療薬企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：パーソナル化されたがん治療薬の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：パーソナル化されたがん治療薬の主要企業の概要を提供し、製品の説明と仕様、パーソナル化されたがん治療薬の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Market Analysis and Insights: Global Personalizing Cancer Drugs Market
The global Personalizing Cancer Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Personalizing Cancer Drugs market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Personalizing Cancer Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Personalizing Cancer Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Personalizing Cancer Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Personalizing Cancer Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Personalizing Cancer Drugs revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Bayer, GlaxoSmithKline, Novartis, Sanofi, Pfizer, Amgen, Merck, Bristol-Myers Squibb and Celgene Corporation, etc.

Market Segmentation
By Company
    Bayer
    GlaxoSmithKline
    Novartis
    Sanofi
    Pfizer
    Amgen
    Merck
    Bristol-Myers Squibb
    Celgene Corporation
    Ariad Pharmaceuticals
    Eli Lilly
    Hoffmann-La Roche
    Boehringer Ingelheim
    Johnson and Johnson
    Teva Pharmaceuticals

Segment by Type
    Immunotherapy
    Targeted Therapy
    Chemotherapy
    Hormone Therapy
    Others

Segment by Application
    Breast Cancer
    Blood Cancer
    Gastrointestinal Cancer
    Prostate Cancer
    Skin Cancer
    Lung Cancer
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Personalizing Cancer Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Personalizing Cancer Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Personalizing Cancer Drugs revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Personalizing Cancer Drugs Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Immunotherapy
    Table 3. Key Players of Targeted Therapy
    Table 4. Key Players of Chemotherapy
    Table 5. Key Players of Hormone Therapy
    Table 6. Key Players of Others
    Table 7. Global Personalizing Cancer Drugs Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 8. Global Personalizing Cancer Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 9. Global Personalizing Cancer Drugs Market Size by Region (2019-2024) & (US$ Million)
    Table 10. Global Personalizing Cancer Drugs Market Share by Region (2019-2024)
    Table 11. Global Personalizing Cancer Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 12. Global Personalizing Cancer Drugs Market Share by Region (2025-2030)
    Table 13. Personalizing Cancer Drugs Market Trends
    Table 14. Personalizing Cancer Drugs Market Drivers
    Table 15. Personalizing Cancer Drugs Market Challenges
    Table 16. Personalizing Cancer Drugs Market Restraints
    Table 17. Global Personalizing Cancer Drugs Revenue by Players (2019-2024) & (US$ Million)
    Table 18. Global Personalizing Cancer Drugs Revenue Share by Players (2019-2024)
    Table 19. Global Top Personalizing Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Personalizing Cancer Drugs as of 2023)
    Table 20. Global Personalizing Cancer Drugs Industry Ranking 2022 VS 2023 VS 2024
    Table 21. Global 5 Largest Players Market Share by Personalizing Cancer Drugs Revenue (CR5 and HHI) & (2019-2024)
    Table 22. Global Key Players of Personalizing Cancer Drugs, Headquarters and Area Served
    Table 23. Global Key Players of Personalizing Cancer Drugs, Product and Application
    Table 24. Global Key Players of Personalizing Cancer Drugs, Product and Application
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Personalizing Cancer Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 27. Global Personalizing Cancer Drugs Revenue Market Share by Type (2019-2024)
    Table 28. Global Personalizing Cancer Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 29. Global Personalizing Cancer Drugs Revenue Market Share by Type (2025-2030)
    Table 30. Global Personalizing Cancer Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 31. Global Personalizing Cancer Drugs Revenue Share by Application (2019-2024)
    Table 32. Global Personalizing Cancer Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 33. Global Personalizing Cancer Drugs Revenue Share by Application (2025-2030)
    Table 34. North America Personalizing Cancer Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 35. North America Personalizing Cancer Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 36. North America Personalizing Cancer Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 37. North America Personalizing Cancer Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 38. North America Personalizing Cancer Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 39. North America Personalizing Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 40. North America Personalizing Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 41. Europe Personalizing Cancer Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 42. Europe Personalizing Cancer Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 43. Europe Personalizing Cancer Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 44. Europe Personalizing Cancer Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 45. Europe Personalizing Cancer Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 46. Europe Personalizing Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 47. Europe Personalizing Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 48. China Personalizing Cancer Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 49. China Personalizing Cancer Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 50. China Personalizing Cancer Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 51. China Personalizing Cancer Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 52. Asia Personalizing Cancer Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 53. Asia Personalizing Cancer Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 54. Asia Personalizing Cancer Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 55. Asia Personalizing Cancer Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 56. Asia Personalizing Cancer Drugs Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 57. Asia Personalizing Cancer Drugs Market Size by Region (2019-2024) & (US$ Million)
    Table 58. Asia Personalizing Cancer Drugs Market Size by Region (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Personalizing Cancer Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Personalizing Cancer Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Personalizing Cancer Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Personalizing Cancer Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Personalizing Cancer Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 64. Middle East, Africa, and Latin America Personalizing Cancer Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 65. Middle East, Africa, and Latin America Personalizing Cancer Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 66. Bayer Company Details
    Table 67. Bayer Business Overview
    Table 68. Bayer Personalizing Cancer Drugs Product
    Table 69. Bayer Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 70. Bayer Recent Developments
    Table 71. GlaxoSmithKline Company Details
    Table 72. GlaxoSmithKline Business Overview
    Table 73. GlaxoSmithKline Personalizing Cancer Drugs Product
    Table 74. GlaxoSmithKline Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 75. GlaxoSmithKline Recent Developments
    Table 76. Novartis Company Details
    Table 77. Novartis Business Overview
    Table 78. Novartis Personalizing Cancer Drugs Product
    Table 79. Novartis Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 80. Novartis Recent Developments
    Table 81. Sanofi Company Details
    Table 82. Sanofi Business Overview
    Table 83. Sanofi Personalizing Cancer Drugs Product
    Table 84. Sanofi Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 85. Sanofi Recent Developments
    Table 86. Pfizer Company Details
    Table 87. Pfizer Business Overview
    Table 88. Pfizer Personalizing Cancer Drugs Product
    Table 89. Pfizer Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 90. Pfizer Recent Developments
    Table 91. Amgen Company Details
    Table 92. Amgen Business Overview
    Table 93. Amgen Personalizing Cancer Drugs Product
    Table 94. Amgen Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 95. Amgen Recent Developments
    Table 96. Merck Company Details
    Table 97. Merck Business Overview
    Table 98. Merck Personalizing Cancer Drugs Product
    Table 99. Merck Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 100. Merck Recent Developments
    Table 101. Bristol-Myers Squibb Company Details
    Table 102. Bristol-Myers Squibb Business Overview
    Table 103. Bristol-Myers Squibb Personalizing Cancer Drugs Product
    Table 104. Bristol-Myers Squibb Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 105. Bristol-Myers Squibb Recent Developments
    Table 106. Celgene Corporation Company Details
    Table 107. Celgene Corporation Business Overview
    Table 108. Celgene Corporation Personalizing Cancer Drugs Product
    Table 109. Celgene Corporation Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 110. Celgene Corporation Recent Developments
    Table 111. Ariad Pharmaceuticals Company Details
    Table 112. Ariad Pharmaceuticals Business Overview
    Table 113. Ariad Pharmaceuticals Personalizing Cancer Drugs Product
    Table 114. Ariad Pharmaceuticals Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 115. Ariad Pharmaceuticals Recent Developments
    Table 116. Eli Lilly Company Details
    Table 117. Eli Lilly Business Overview
    Table 118. Eli Lilly Personalizing Cancer Drugs Product
    Table 119. Eli Lilly Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 120. Eli Lilly Recent Developments
    Table 121. Hoffmann-La Roche Company Details
    Table 122. Hoffmann-La Roche Business Overview
    Table 123. Hoffmann-La Roche Personalizing Cancer Drugs Product
    Table 124. Hoffmann-La Roche Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 125. Hoffmann-La Roche Recent Developments
    Table 126. Boehringer Ingelheim Company Details
    Table 127. Boehringer Ingelheim Business Overview
    Table 128. Boehringer Ingelheim Personalizing Cancer Drugs Product
    Table 129. Boehringer Ingelheim Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 130. Boehringer Ingelheim Recent Developments
    Table 131. Johnson and Johnson Company Details
    Table 132. Johnson and Johnson Business Overview
    Table 133. Johnson and Johnson Personalizing Cancer Drugs Product
    Table 134. Johnson and Johnson Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 135. Johnson and Johnson Recent Developments
    Table 136. Teva Pharmaceuticals Company Details
    Table 137. Teva Pharmaceuticals Business Overview
    Table 138. Teva Pharmaceuticals Personalizing Cancer Drugs Product
    Table 139. Teva Pharmaceuticals Revenue in Personalizing Cancer Drugs Business (2019-2024) & (US$ Million)
    Table 140. Teva Pharmaceuticals Recent Developments
    Table 141. Research Programs/Design for This Report
    Table 142. Key Data Information from Secondary Sources
    Table 143. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Personalizing Cancer Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Personalizing Cancer Drugs Market Share by Type: 2023 VS 2030
    Figure 3. Immunotherapy Features
    Figure 4. Targeted Therapy Features
    Figure 5. Chemotherapy Features
    Figure 6. Hormone Therapy Features
    Figure 7. Others Features
    Figure 8. Global Personalizing Cancer Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 9. Global Personalizing Cancer Drugs Market Share by Application: 2023 VS 2030
    Figure 10. Breast Cancer Case Studies
    Figure 11. Blood Cancer Case Studies
    Figure 12. Gastrointestinal Cancer Case Studies
    Figure 13. Prostate Cancer Case Studies
    Figure 14. Skin Cancer Case Studies
    Figure 15. Lung Cancer Case Studies
    Figure 16. Others Case Studies
    Figure 17. Personalizing Cancer Drugs Report Years Considered
    Figure 18. Global Personalizing Cancer Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 19. Global Personalizing Cancer Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 20. Global Personalizing Cancer Drugs Market Share by Region: 2023 VS 2030
    Figure 21. Global Personalizing Cancer Drugs Market Share by Players in 2023
    Figure 22. Global Top Personalizing Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Personalizing Cancer Drugs as of 2023)
    Figure 23. The Top 10 and 5 Players Market Share by Personalizing Cancer Drugs Revenue in 2023
    Figure 24. North America Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. North America Personalizing Cancer Drugs Market Share by Type (2019-2030)
    Figure 26. North America Personalizing Cancer Drugs Market Share by Application (2019-2030)
    Figure 27. North America Personalizing Cancer Drugs Market Share by Country (2019-2030)
    Figure 28. United States Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Canada Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Europe Personalizing Cancer Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 31. Europe Personalizing Cancer Drugs Market Share by Type (2019-2030)
    Figure 32. Europe Personalizing Cancer Drugs Market Share by Application (2019-2030)
    Figure 33. Europe Personalizing Cancer Drugs Market Share by Country (2019-2030)
    Figure 34. Germany Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. France Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. U.K. Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Italy Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Russia Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. Nordic Countries Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. China Personalizing Cancer Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 41. China Personalizing Cancer Drugs Market Share by Type (2019-2030)
    Figure 42. China Personalizing Cancer Drugs Market Share by Application (2019-2030)
    Figure 43. Asia Personalizing Cancer Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 44. Asia Personalizing Cancer Drugs Market Share by Type (2019-2030)
    Figure 45. Asia Personalizing Cancer Drugs Market Share by Application (2019-2030)
    Figure 46. Asia Personalizing Cancer Drugs Market Share by Region (2019-2030)
    Figure 47. Japan Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. South Korea Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 49. China Taiwan Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 50. Southeast Asia Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 51. India Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Australia Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Middle East, Africa, and Latin America Personalizing Cancer Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 54. Middle East, Africa, and Latin America Personalizing Cancer Drugs Market Share by Type (2019-2030)
    Figure 55. Middle East, Africa, and Latin America Personalizing Cancer Drugs Market Share by Application (2019-2030)
    Figure 56. Middle East, Africa, and Latin America Personalizing Cancer Drugs Market Share by Country (2019-2030)
    Figure 57. Brazil Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. Mexico Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 59. Turkey Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 60. Saudi Arabia Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 61. Israel Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 62. GCC Countries Personalizing Cancer Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 63. Bayer Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 64. GlaxoSmithKline Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 65. Novartis Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 66. Sanofi Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 67. Pfizer Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 68. Amgen Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 69. Merck Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 70. Bristol-Myers Squibb Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 71. Celgene Corporation Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 72. Ariad Pharmaceuticals Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 73. Eli Lilly Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 74. Hoffmann-La Roche Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 75. Boehringer Ingelheim Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 76. Johnson and Johnson Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 77. Teva Pharmaceuticals Revenue Growth Rate in Personalizing Cancer Drugs Business (2019-2024)
    Figure 78. Bottom-up and Top-down Approaches for This Report
    Figure 79. Data Triangulation
    Figure 80. Key Executives Interviewed